MAIA Biotechnology Current Debt
| MAIA Stock | USD 2.08 0.07 3.26% |
At present, MAIA Biotechnology's Short Term Debt is projected to increase significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 0.37, whereas Short and Long Term Debt Total is forecasted to decline to about 274.4 K. With a high degree of financial leverage come high-interest payments, which usually reduce MAIA Biotechnology's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.56 | Current Value 0.59 | Quarterly Volatility 0.28459128 |
Given that MAIA Biotechnology's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which MAIA Biotechnology is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of MAIA Biotechnology to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, MAIA Biotechnology is said to be less leveraged. If creditors hold a majority of MAIA Biotechnology's assets, the Company is said to be highly leveraged.
At present, MAIA Biotechnology's Non Current Liabilities Total is projected to increase significantly based on the last few years of reporting. The current year's Change To Liabilities is expected to grow to about 972.7 K, whereas Total Current Liabilities is forecasted to decline to about 2.7 M. MAIA |
MAIA Biotechnology Debt to Cash Allocation
As MAIA Biotechnology follows its natural business cycle, the capital allocation decisions will not magically go away. MAIA Biotechnology's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
MAIA Biotechnology currently holds 7.09 M in liabilities. MAIA Biotechnology has a current ratio of 2.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about MAIA Biotechnology's use of debt, we should always consider it together with its cash and equity.MAIA Biotechnology Total Assets Over Time
MAIA Biotechnology Assets Financed by Debt
The debt-to-assets ratio shows the degree to which MAIA Biotechnology uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.MAIA Biotechnology Debt Ratio | 59.0 |
MAIA Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning MAIA Biotechnology Use of Financial Leverage
MAIA Biotechnology's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures MAIA Biotechnology's total debt position, including all outstanding debt obligations, and compares it with MAIA Biotechnology's equity. Financial leverage can amplify the potential profits to MAIA Biotechnology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if MAIA Biotechnology is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 533.3 K | 274.4 K | |
| Net Debt | -7.2 M | -7.5 M | |
| Short Term Debt | 128 K | 134.4 K | |
| Long Term Debt | 388.6 K | 345.4 K | |
| Short and Long Term Debt | 28.8 K | 25.6 K | |
| Net Debt To EBITDA | 0.35 | 0.37 | |
| Debt To Equity | (0.14) | (0.13) | |
| Debt To Assets | 0.56 | 0.59 | |
| Long Term Debt To Capitalization | (0.17) | (0.18) | |
| Total Debt To Capitalization | (0.16) | (0.15) | |
| Debt Equity Ratio | (0.14) | (0.13) | |
| Debt Ratio | 0.56 | 0.59 | |
| Cash Flow To Debt Ratio | (3.58) | (3.76) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out the analysis of MAIA Biotechnology Fundamentals Over Time. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.